1223487-18-0

Upstream product

• 1422707-31-0 methyl (2S)-1-{[3-(benzyloxy)-6,7-dimethoxy-9-phenanthryl]methyl}-5-oxopyrrolidine-2-carboxylate 
• 26847-68-7 6,7-dimethoxy-3-benzoxy-9-phenanthrenecarboxylic acid methyl ester 
• 100-39-0 benzyl bromide 
• 1449298-72-9 3-hydroxy-6,7-dimethoxy-9-phenanthrenecarboxylic acid methyl ester 
• 1223487-14-6 C₃₂H₃₃NO₆ 

Downstream Products

• 1223487-21-5 (13aS)-3-(benzyloxy)-6,7-dimethoxy-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-dione 
• 1338360-74-9 (13aS)-3-(benzyloxy)-6,7-dimethoxy-12,13,13a,14-tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11(9H)-one 
• 1422707-34-3 (13aS)-3-(benzyloxy)-6,7-dimethoxy-9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline 

Relevant academic research and scientific papers

Stereospecific synthesis and biological evaluation of monodesmethyl metabolites of (+)-13a-(S)-deoxytylophorinine as potential antitumor agents

Three major monodesmethyl metabolites of (+)-13a-(S)-deoxytylophorinine were synthesized stereospecifically and their configurations at C-13a were determined. Biological assays revealed that one of the metabolites, 3-O-desmethyl-13a-(S)-deoxytylophorinine

Asymmetric synthesis of phenanthroindolizidine alkaloids with hydroxyl group at the C14 position and evaluation of their antitumor activities

The asymmetric total synthesis of the strongly cytotoxic phenanthroindolizidine alkaloid 3 was achieved. Using the same route, various derivatives were also synthesized. Cytotoxicity of those synthetic compounds was evaluated and compounds 19, 23, and 27

PHENANTHROINDOLIZIDINE DERIVATIVE AND NF B INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT

A novel compound having an excellent NFκB inhibitory effect is provided. Specifically disclosed is a compound represented by the following formula (1) or a salt thereof: wherein, R1 represents a hydrogen atom, a lower alkyl group, or the like;